Inflammatix Data in Journal of Clinical Microbiology Validate Accuracy, Robustness, and Ease of Use of TriVerity™ Test System
Publication demonstrates superior analytical performance of TriVerity in assessing patients with suspected acute infection or sepsis
SUNNYVALE, Calif., Sept. 2, 2025 /PRNewswire/ — Inflammatix, a pioneering host response diagnostics company, today announced the publication of analytical data in the Journal of Clinical Microbiology (JCM) that validate the benefits of the TriVerity™ Test System (TriVerity), a first-in-class molecular blood test to help emergency department (ED) physicians quickly and accurately triage patients with suspected acute infection or sepsis. The data demonstrate the high accuracy and precision, fast turnaround time, and ease of use of TriVerity, as well as the reliability of the Myrna™ Instrument, on which the test is run.
As reported in JCM, TriVerity provides superior analytical performance in terms of reproducibility, sensitivity, specificity, stability, and operational usability. The test generates results within a clinically meaningful time frame (approximately 30 minutes), with minimal operator hands-on time (under 1 minute per test performed). The analytical data support the use of TriVerity as a reliable and user-friendly tool in helping ED clinicians manage patients with suspected infection and/or sepsis.
